Insulet will acquire insulin pump patents from Bigfoot Biomedical for $25m, which Bigfoot will use to expand its Unity diabetes management system. Insulet also announced the acquisition of automated insulin delivery assets held by Automated Glucose Control.

Bigfoot Biomedical’s Unity system pairs continuous glucose monitoring with smart insulin pen caps, giving patients recommendations on insulin dosing. Because patient interaction is involved, Bigfoot Biomedical can deliver insulin pump-like results to pump-ineligible type II diabetics.

Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.